NervGen announced the FDA informed the company that an expanded access protocol for NVG-291 may proceed, and as a result, the company has initiated an expanded access policy to allow treatment use of the investigational product NVG-291, for those individuals with spinal cord injury who have participated in NervGen clinical trials and meet specific eligibility criteria, after the company received a request from a physician for expanded access to NVG-291 for a subject who participated in the chronic cohort of the Phase 1b/2a clinical trial. Read the full news release: https://lnkd.in/ge8hThJd #SpinalCordInjury #SCI #announcement #news
NervGen Pharma Corp.
Biotechnology Research
Vancouver, British Columbia 2,106 followers
Restoring Life's Potential by Creating Innovative Solutions for the Treatment of Nervous System Damage
About us
NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing innovative treatments for nervous system damage, due to injury or disease. NervGen’s lead drug candidate, NVG-291, is a first of its kind experimental drug administered by injection under the skin. NVG-291 relieves the inhibitory effects of CSPGs and thus enables nervous system repair. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory. NVG-291 entered Phase 1 clinical trials in 2021. After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.
- Website
-
http://www.nervgen.com
External link for NervGen Pharma Corp.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Vancouver, British Columbia
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
Get directions
2955 Virtual Way
480
Vancouver, British Columbia V5M 4X6, CA
Employees at NervGen Pharma Corp.
-
John Ruffolo
Founder & Managing Partner at Maverix Private Equity. Founder, OMERS Ventures and Co-Founder, Council of Canadian Innovators
-
Matvey Lukashev
-
Neil Klompas
Chief Executive Officer, Augurex Life Sciences
-
Krista McKerracher
Board Member, Strategic Advisor, Retired Corporate Executive Leader
Updates
-
NervGen Pharma Corp. reposted this
Join NervGen Pharma Corp. (#NGEN; #NGENF) for a virtual investor event on Wednesday, April 9, 2025 at 10:00 a.m. ET. This event will feature key opinion leaders, Dr. Monica Perez (Shirley Ryan AbilityLab) and Dr. Steven Kirshblum (Rutgers New Jersey Medical School), who will join company management to discuss the unmet medical need and current treatment landscape for individuals with spinal cord injury. Register here: https://bit.ly/42o06qD
-
-
In this The Scientist Innovation Spotlight article, NervGen’s President & CEO, Mike Kelly, discusses the need for SCI research, the challenges of nervous system repair, and how our lead drug candidate, NVG-291, aims to break barriers in spinal cord injury treatment. Spinal cord injuries are estimated to affect up to 500,000 people worldwide each year, often leading to lifelong challenges. At NervGen, we’re dedicated to developing innovative therapies that go beyond symptom management—potentially enabling nervous system repair. Read the full article: https://lnkd.in/eXAstZRw #SCI #SpinalCordInjury #Neurorepair #Biotech #Innovation
-
-
Mike Kelly, NervGen’s President & CEO, will be presenting at RIConferences Virtual Life Sciences Investor Forum hosted by OTC Markets Group and VirtualInvestorConferences. com on Thursday, March 13, 2025, at noon EDT. Members of management will be available for virtual one-on-one investor meetings on March 13-14 & 17-18. See here for the full news release: https://lnkd.in/euY3pfYf #news
-
-
NervGen announced that the first subject has been enrolled and dosed in the subacute cohort of the Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial evaluating its lead candidate, NVG-291, in individuals with spinal cord injury. Read the full news release: https://lnkd.in/ehJFPNFv #SpinalCordInjury #SCI #ClinicalTrial #announcement #news
-
-
Mike Kelly, NervGen’s President & CEO, will be participating in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025, at 8:40 a.m. EST. Members of management will be available for virtual one-on-one investor meetings during the conference. See here for the full news release: https://lnkd.in/ehRX2Kty #news
-
-
NervGen’s Senior Vice President, Technical Operations, Chuck Olson, will participate in the inaugural Pharmaceutical Online Live event: “Opportunities For Innovation in Peptide Manufacturing.” In this interactive event, Chuck will share insights on peptide manufacturing and ways to improve efficiency, yields, and cost-effectiveness. Date: Wednesday, January 22, 2025 Time: 11:00 AM ET Register for the event: https://lnkd.in/ewb89eMH
The peptide market is booming 💥, driving manufacturers to enhance processes and capacity. This creates a unique opportunity to re-evaluate the way we manufacture these drugs. 🔹What are the biggest changes in peptide manufacturing? 🔹How can it continue to improve? Join us in exploring ways to improve peptide manufacturing to produce higher yields at lower costs. 🎙️ Featured Speaker: Chuck Olson D.Sc., Senior Vice President, Technical Operations, NervGen Pharma Corp. Don’t miss the inaugural Pharmaceutical Online Live on Wednesday, January 22, 2025 at 11:00 AM. Reserve your spot here: https://lnkd.in/ekg6mqKc Registration is free thanks to the support of Federal Equipment Company.
-
-
We are deeply saddened by the passing of Dr. Jerry Silver, whose groundbreaking work laid the foundation for our mission to help individuals with spinal cord injury. Read our full statement honoring his legacy: https://lnkd.in/ew2TwUmv
-
-
NervGen today announced that it has completed enrollment in the chronic cohort of its Phase 1b/2a clinical trial for its investigational lead molecule, NVG-291, in individuals with spinal cord injury. Additionally, the company has initiated screening subjects for the subacute cohort of the study. Read the full news release: https://lnkd.in/e_v3nhTB #SpinalCordInjury #SCI #ClinicalTrial #announcement #news
-
-
In a recent podcast interview with Ira Pastor of Progress, Potential, and Possibilities, NervGen’s President & CEO, Mike Kelly, gave a deep dive into NervGen’s lead molecule, NVG-291, explained the benefits of conducting a clinical trial with a chronic SCI population, and described the primary and secondary endpoints of NervGen’s current Phase 1b/2a trial in traumatic spinal cord injury. Watch the full interview: https://lnkd.in/ekzJEZeA #SpinalCordInjury #SCI
-